Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Mathai, L. Gao, N. Rafaels, R. Damico, T. Kolb, K. Barnes, P. Hassoun (Baltimore, United States Of America). Polymorphisms in angiotensin converting enzyme gene are associated with risk of development of and disease severity in scleroderma-related pulmonary arterial hypertension. Eur Respir J 2012; 40: Suppl. 56, 4553

Member's Comments

No comment yet.

Related content which might interest you: Differences in the activity of the angiotensin converting enzyme 2 axis in patients with idiopathic pulmonary arterial hypertension and congenital heart defect related pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Etiology specific reductions in pulmonary endothelial angiotensin converting enzyme activity in patients with PAH Source: Eur Respir J 2006; 28: Suppl. 50, 658s Year: 2006 A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension Source: Eur Respir J, 51 (6) 1702638; 10.1183/13993003.02638-2017 Year: 2018 Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression Source: Eur Respir J 2008; 32: 1004-1008 Year: 2008 The role of angiotensin converting enzyme gene polymorphism in pulmonary thromboembolism Source: Annual Congress 2004 - Pulmonary embolism Year: 2004 Angiotensin-converting enzyme genotype modulates pulmonary artery pressure in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 560s Year: 2004 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Prognostic risk factors of disease worsening in patients with functional class II pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene Source: Eur Respir J 2001; 17: 1065-1069 Year: 2001 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Angiotensin-converting-enzyme gene polymorphism and susceptibility to chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 195s Year: 2002 Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis Source: Eur Respir J 2002; 20: 59-65 Year: 2002 Effect of phosphodiesterase 5 inhibitor in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 The role of the biomarker and the genetic polymorphism of endothelin-1 in pulmonary arterial hypertension among Egyptians Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Fibrinogen AaThr312Ala polymorphism predisposes to chronic thromboembolic pulmonary hypertension Source: Annual Congress 2007 - Acute and chronic pulmonary embolism Year: 2007 Double combination therapy in patients with pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 No association of angiotensin I-converting enzyme gene polymorphism and pulmonary function in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 173s Year: 2003 Tissue inhibitor of metalloproteinases-;2 gene polymorphisms in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 748-752 Year: 2001